Literature DB >> 35722745

Clinical and genetic characterization of CACNA1A-related disease.

Amy R Lipman1, Xiao Fan2,3, Yufeng Shen3,4,5, Wendy K Chung2,6.   

Abstract

Pathogenic variants in the CACNA1A gene have been associated with episodic ataxia type 2, familial hemiplegic migraine, and spinocerebellar ataxia 6. With increasing use of clinical genetic testing, associations have expanded to include developmental delay, epilepsy, paroxysmal dystonia, and neuropsychiatric disorders. We report 47 individuals with 33 unique likely pathogenic or pathogenic CACNA1A variants. A machine learning method, funNCion, was used to predict loss-of-function (LoF)/gain-of-function (GoF) impact of genetic variants, and a heuristic severity score was designed to analyze genotype/phenotype correlations. Commonly reported phenotypes include developmental delay/intellectual disability (96%), hemiplegic migraines (36%), episodic ataxia type 2 (32%), epilepsy (55%), autism spectrum disorder (23%), and paroxysmal tonic upward gaze (36%). Severity score was significantly higher for predicted GoF variants, variants in the S5/S6 helices, and the recurrent p.Val1392Met variant. Seizures/status epilepticus were correlated with GoF and were more frequent in those with the p.Val1392Met variant. Our findings demonstrate a breadth of disease severity in CACNA1A-related disease and suggest that the clinical phenotypic heterogeneity likely reflects diverse molecular phenotypes. A better understanding of the natural history of CACNA1A-related disease and genotype/phenotype correlations will help inform prognosis and prepare for future clinical trials.
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CACNA1A; autism spectrum disorder; developmental delay; epilepsy; episodic ataxia; hemiplegic migraine; paroxysmal tonic upward gaze

Mesh:

Substances:

Year:  2022        PMID: 35722745      PMCID: PMC9458680          DOI: 10.1111/cge.14180

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.296


  26 in total

1.  Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine.

Authors:  E E Kors; G M Terwindt; F L Vermeulen; R B Fitzsimons; P E Jardine; P Heywood; S Love; A M van den Maagdenberg; J Haan; R R Frants; M D Ferrari
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

2.  Predicting functional effects of missense variants in voltage-gated sodium and calcium channels.

Authors:  Henrike O Heyne; David Baez-Nieto; Sumaiya Iqbal; Duncan S Palmer; Andreas Brunklaus; Patrick May; Katrine M Johannesen; Stephan Lauxmann; Johannes R Lemke; Rikke S Møller; Eduardo Pérez-Palma; Ute I Scholl; Steffen Syrbe; Holger Lerche; Dennis Lal; Arthur J Campbell; Hao-Ran Wang; Jen Pan; Mark J Daly
Journal:  Sci Transl Med       Date:  2020-08-12       Impact factor: 17.956

3.  Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.

Authors:  R A Ophoff; G M Terwindt; M N Vergouwe; R van Eijk; P J Oefner; S M Hoffman; J E Lamerdin; H W Mohrenweiser; D E Bulman; M Ferrari; J Haan; D Lindhout; G J van Ommen; M H Hofker; M D Ferrari; R R Frants
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms.

Authors:  Lena Damaj; Alexis Lupien-Meilleur; Anne Lortie; Émilie Riou; Luis H Ospina; Louise Gagnon; Catherine Vanasse; Elsa Rossignol
Journal:  Eur J Hum Genet       Date:  2015-03-04       Impact factor: 4.246

5.  Novel frameshift mutation in the CACNA1A gene causing a mixed phenotype of episodic ataxia and familiar hemiplegic migraine.

Authors:  S Kinder; C Ossig; M Wienecke; A Beyer; M von der Hagen; A Storch; M Smitka
Journal:  Eur J Paediatr Neurol       Date:  2014-11-03       Impact factor: 3.140

6.  CACNA1A-associated epilepsy: Electroclinical findings and treatment response on seizures in 18 patients.

Authors:  Marie Le Roux; Magalie Barth; Sophie Gueden; Patrick Desbordes de Cepoy; Alec Aeby; Catheline Vilain; Edouard Hirsch; Anne de Saint Martin; Vincent des Portes; Gaëtan Lesca; Audrey Riquet; Laurence Chaton; Nathalie Villeneuve; Laurent Villard; Claude Cances; Luc Valton; Florence Renaldo; Anne-Isabelle Vermersch; Cecilia Altuzarra; Marie-Ange Nguyen-Morel; Julien Van Gils; Chloé Angelini; Arnaud Biraben; Lionel Arnaud; Florence Riant; Patrick Van Bogaert
Journal:  Eur J Paediatr Neurol       Date:  2021-05-26       Impact factor: 3.140

7.  Identification of novel and recurrent CACNA1A gene mutations in fifteen patients with episodic ataxia type 2.

Authors:  Elide Mantuano; Silvia Romano; Liana Veneziano; Cinzia Gellera; Barbara Castellotti; Sara Caimi; Daniela Testa; Margherita Estienne; Giovanna Zorzi; Marianna Bugiani; Yusuf A Rajabally; Maria J Garcìa Barcina; Serena Servidei; Aurora Panico; Marina Frontali; Caterina Mariotti
Journal:  J Neurol Sci       Date:  2010-02-02       Impact factor: 3.181

Review 8.  Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation.

Authors:  A H Stam; G-J Luijckx; B T Poll-Thé; I B Ginjaar; R R Frants; J Haan; M D Ferrari; G M Terwindt; A M J M van den Maagdenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-10       Impact factor: 10.154

Review 9.  From Genotype to Phenotype: Expanding the Clinical Spectrum of CACNA1A Variants in the Era of Next Generation Sequencing.

Authors:  Elisabetta Indelicato; Sylvia Boesch
Journal:  Front Neurol       Date:  2021-03-02       Impact factor: 4.003

10.  Mutation Spectrum in the CACNA1A Gene in 49 Patients with Episodic Ataxia.

Authors:  Cèlia Sintas; Oriel Carreño; Noèlia Fernàndez-Castillo; Roser Corominas; Marta Vila-Pueyo; Claudio Toma; Ester Cuenca-León; Isabel Barroeta; Carles Roig; Víctor Volpini; Alfons Macaya; Bru Cormand
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.